Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men

Steroids

Volumn 77, Issue 5, 2012, Pages 454-460

  Rubinow, Katya B ^a   Tang, Chongren ^a   Hoofnagle, Andrew N ^a,b   Snyder, Christin N ^a,c   Amory, John K ^a,b   Heinecke, Jay W ^a   Page, Stephanie T ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Good Samaritan Medical Office   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Cardiovascular disease; Estradiol; HDL cholesterol; Testosterone

Indexed keywords

ACYLINE; ANASTROZOLE; APOLIPOPROTEIN B; CHOLESTEROL; CLUSTERIN; ESTRADIOL; GONADORELIN ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SEX HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASTRATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANDROGENS; APOLIPOPROTEINS B; AROMATASE INHIBITORS; CHOLESTEROL; CHOLESTEROL, HDL; CLUSTERIN; DRUG ADMINISTRATION SCHEDULE; FASTING; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NITRILES; OLIGOPEPTIDES; TESTOSTERONE; TIME FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 84858335907     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.01.002     Document Type: Article

References (41)

1. F.C. Wu, and A. von Eckardstein Androgens and coronary artery disease Endocr Rev 24 2003 183 217 (Pubitemid 36515284)
2. G.A. Laughlin, E. Barrett-Connor, and J. Bergstrom Low serum testosterone and mortality in older men J Clin Endocrinol Metab 93 2008 68 75
3. T. Vikan, H. Schirmer, I. Njolstad, and J. Svartberg Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study Eur J Endocrinol 161 2009 435 442
4. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
5. S.M. Gordon, S. Hofmann, D.S. Askew, and W.S. Davidson High density lipoprotein: it's not just about lipid transport anymore Trends Endocrinol Metab 22 2010 9 15
6. T. Vaisar, S. Pennathur, P.S. Green, S.A. Gharib, A.N. Hoofnagle, and M.C. Cheung Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756 (Pubitemid 46348533)
7. A.V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, and K. Jafri Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
8. A.N. Hoofnagle, M. Wu, A.K. Gosmanova, J.O. Becker, E.M. Wijsman, and J.D. Brunzell Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia Arterioscler Thromb Vasc Biol 30 2010 2528 2534
9. T. Vaisar, P. Mayer, E. Nilsson, X.Q. Zhao, R. Knopp, and B.J. Prazen HDL in humans with cardiovascular disease exhibits a proteomic signature Clin Chim Acta 411 2010 972 979
10. Rubinow KB, Snyder CN, Hoofnagle AN, Amory JK, Page ST. Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol (Oxf), in press.
11. K.L. Herbst, A.D. Coviello, S. Page, J.K. Amory, B.D. Anawalt, and W.J. Bremner A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men J Clin Endocrinol Metab 89 2004 5959 5965 (Pubitemid 39628400)
12. D.T. Vallance, D.J. Byrne, and A.F. Winder Precipitation procedures used to isolate high density lipoprotein with particular reference to effects on apo A-I-only particles and lipoprotein(a) Clin Chim Acta 229 1994 77 85 (Pubitemid 24269174)
13. P.J. Kersey, J. Duarte, A. Williams, Y. Karavidopoulou, E. Birney, and R. Apweiler The International Protein Index: an integrated database for proteomics experiments Proteomics 4 2004 1985 1988 (Pubitemid 38880363)
14. W. Yan, H. Lee, E.W. Deutsch, C.A. Lazaro, W. Tang, and E. Chen A dataset of human liver proteins identified by protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry Mol Cell Proteomics 3 2004 1039 1041 (Pubitemid 40361237)
15. A.I. Nesvizhskii, A. Keller, E. Kolker, and R. Aebersold A statistical model for identifying proteins by tandem mass spectrometry Anal Chem 75 2003 4646 4658 (Pubitemid 37082259)
16. J.W. Tukey, J.L. Ciminera, and J.F. Heyse Testing the statistical certainty of a response to increasing doses of a drug Biometrics 41 1985 295 301
17. H. Karlsson, P. Leanderson, C. Tagesson, and M. Lindahl Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry Proteomics 5 2005 1431 1445
18. J. Heinecke HDL and cardiovascular-disease risk-time for a new approach? N Engl J Med 364 2011 170 171
19. M. Suzuki, D.K. Pritchard, L. Becker, A.N. Hoofnagle, N. Tanimura, and T.K. Bammler High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide Circulation 122 2010 1919 1927
20. D.J. Rader, E.T. Alexander, G.L. Weibel, J. Billheimer, and G.H. Rothblat The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J Lipid Res 50 Suppl 2009 S189 194
21. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
22. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
23. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011;161:538-543.
24. J.A. Glomset The metabolic role of lecithin: cholesterol acyltransferase: perspectives from pathology Adv Lipid Res 11 1973 1 65
25. D.J. Gordon, and B.M. Rifkind High-density lipoprotein - the clinical implications of recent studies N Engl J Med 321 1989 1311 1316 (Pubitemid 19267219)
26. A.R. Tall Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins J Intern Med 263 2008 256 273 (Pubitemid 351207349)
27. M. de la Llera-Moya, D. Drazul-Schrader, B.F. Asztalos, M. Cuchel, D.J. Rader, and G.H. Rothblat The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler Thromb Vasc Biol 30 2010 796 801
28. C. Langer, B. Gansz, C. Goepfert, T. Engel, Y. Uehara, and G. von Dehn Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages Biochem Biophys Res Commun 296 2002 1051 1057
29. T.S. Mikkola, M.S. Anthony, and T.B. Clarkson St Clair RW. Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens Metabolism 51 2002 523 530 (Pubitemid 34406573)
30. A. von Eckardstein, D. Crook, J. Elbers, J. Ragoobir, B. Ezeh, and F. Helmond Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux Clin Endocrinol (Oxf) 58 2003 49 58 (Pubitemid 36098848)
31. H.M. Behre, A. Bockers, A. Schlingheider, and E. Nieschlag Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men Clin Endocrinol (Oxf) 40 1994 241 248 (Pubitemid 24193155)
32. D. Buchter, H.M. Behre, S. Kliesch, A. Chirazi, E. Nieschlag, and G. Assmann Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin Exp Clin Endocrinol Diabetes 107 1999 522 529
33. A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H.M. Behre Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a) J Clin Endocrinol Metab 82 1997 3367 3372 (Pubitemid 27419089)
34. C.J. Bagatell, R.H. Knopp, J.E. Rivier, and W.J. Bremner Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men J Clin Endocrinol Metab 78 1994 855 861 (Pubitemid 24118078)
35. J.Q. Purnell, L.B. Bland, M. Garzotto, D. Lemmon, E.M. Wersinger, and C.W. Ryan Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer J Lipid Res 47 2006 349 355 (Pubitemid 43276920)
36. R. Movva, and D.J. Rader Laboratory assessment of HDL heterogeneity and function Clin Chem 54 2008 788 800 (Pubitemid 351671595)
37. L.V. July, M. Akbari, T. Zellweger, E.C. Jones, S.L. Goldenberg, and M.E. Gleave Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy Prostate 50 2002 179 188 (Pubitemid 34137445)
38. T. Nieminen, M. Kahonen, and T. Lehtimaki The effects of apoA-I/C-III/A-IV, apoE and apoB polymorphisms on carotid artery intima-media thickness Future Cardiol 2 2006 179 186
39. G.M. Dallinga-Thie, R.P. Dullaart, and A. van Tol Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins Curr Opin Lipidol 18 2007 251 257 (Pubitemid 46743047)
40. N. Duverger, G. Tremp, J.M. Caillaud, F. Emmanuel, G. Castro, and J.C. Fruchart Protection against atherogenesis in mice mediated by human apolipoprotein A-IV Science 273 1996 966 968 (Pubitemid 26275175)
41. R.A. Srivastava, R.T. Kitchens, and G. Schonfeld Regulation of the apolipoprotein AIV gene expression by estrogen differs in rat and mouse Eur J Biochem 222 1994 507 514 (Pubitemid 24204922)